Dopaminergic dysfunction in Parkinsonism: New lessons from imaging

Neuroscientist

Volumn 5, Issue 5, 1999, Pages 333-340

  Marek, Kenneth ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal ganglia; Dopamine transporter; FDOPA; Parkinson's disease; PET; SPECT

Indexed keywords

DOPAMINE;

BASAL GANGLION; BRAIN SCINTISCANNING; DOPAMINE BRAIN LEVEL; DOPAMINE UPTAKE; HUMAN; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROTRANSMISSION; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0032886489     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849900500519     Document Type: Review

References (62)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely, and Jones; 1819.
2. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitleberger F. Brain dopamine and the syndromes of Parkinson and Huntington, clinical, morphological, and neurochemical correlates. J Neurol Sci 1973;20:415-455.
3. Calne DB. Is idiopathic Parkinsonism the consequence of an event or a process? Neurology 1993;44:5-10.
4. Langston J, Koller W. The next frontier in Parkinson's disease: presymptomatic detection. Neurology 1991;41:5-7.
5. Duvoisin R. The genetics of Parkinson's disease. Adv Neurol 1993;60:306-315.
6. Wichman T, Vitek J, DeLong M. Parkinson's disease and the basal ganglia: lessons from the laboratory and from neurosurgery. THE NEUROSCIENTIST 1995;1:236-244.
7. Kish SJ, Shannak K, Homykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880.
8. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
9. McGeer PL, Itagaki S, Akiyama S, McGeer EG. Rate of cell death in Parkinsonism is an active neuropathological process. Ann Neurol 1988;24:574.
10. Martilla R, Rinne U. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand 1967;43:9-61.
11. Rajput A, Offord K, Beard C, Kurland L. Epidemiology of Parkinson's disease. Incidence, classification and mortality. Ann Neurol 1984:278:278-87.
12. Tanner C. Epidemiologic clues to the cause of Parkinson's disease. In: Fahn S, Marsden CD, editors. Movement disorders 3. Oxford: Butterworth-Heinemann; 1994. p. 124-146.
13. Hoehn M, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
14. Calne D. Treatment of Parkinson's disease. N Engl J Med 1993; 329:1021-1027.
15. Koller W, Silver D, Lieberman A. An algorithm for managing Parkinson's disease. Neurology 1994;44:S1-S52.
16. Olanow C. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997;S26-S33.
17. Ogawa N. Possible neuroprotective therapy for Parkinson's disease. Acta Med Okayama 1995;49:179-185.
18. Freese A, Stern M, Kaplitt M, O'Connor WM, Abbey MV, O'Connor MJ, et al. Prospects for gene therapy in Parkinson's disease. Mov Disord 1996;11:469-488.
19. Phelps M. Positron emission tomography (PET). In: Mazziota JC, Gilman S, editors. Clinical brain imaging: principles and applications. Philadelphia: FA Davis; 1992. p. 71-107.
20. Lassen N, Holm S. Single photon emission computerized tomography (SPECT). In: Mazziota JC, Gilman S, editors. Clinical brain imaging: principles and applications. Philadelphia: FA Davis; 1992. p. 108-134.
21. Friston K, Frith C, Liddle P, Dolan R, Lammertsma A, Frackowiak R. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab 1990;10:458-466.
22. Brooks DJ. Functional imaging in relation to Parkinsonian syndromes. J Neurol Sci 1993;115:1-17.
23. Calne DB, Langston JW, Martin WRW, Stoessl AJ, Ruth TJ, Adam MJ, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-248.
24. Leenders K, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-1298.
25. Nahmias C, Gamett ES, Firnau G, Lang A. Striatal dopamine distribution in Parkinsonian patients during life. J Neurol Sci 1985; 69:223-230.
26. 123I]IACFT): initial experience in humans. Neuroscience-Net [serial online] 1996;1(#00010):[28 screens]. Available from: URL: http://www.neuroscience.com/iacft/htm/index.html.
27. 123I]FP-SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62:133-140.
28. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomography imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked decline in mild Parkinson's disease. Ann Neurol 1993:34:423-131.
29. Innis RB, Seibyl JP, Scanley BE, Lamelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A 1993;90:11965-11969.
30. 123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:415-421.
31. 123I]b-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease. Ann Neurol 1995;38:589-598.
32. 123I]b-CIT and SPECT. J Neural Transm 1997;50 Suppl:9-24.
33. Brooks D, Ibanez V, Sawle G, Playford ED, Quinn N, Mathias CJ, et al. Striatal D2 Receptor Status in Patients with Parkinson's Disease, Striatonigral Degeneration, and Progressive Supranuclear Palsy, Measured with 11C-Raclopride and Positron Emission Tomography. Ann Neurol 1992;31:184-192.
34. Tatsch K, Schwarz J, Oertel W, Kirsch C. Dopamine D2 receptor imaging with I-123 IBZM SPECT to differentiate idiopathic from other Parkinson syndromes. J Nucl Med 1992;33:917-918.
35. 11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44:1325-1329.
36. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:1142-1146.
37. Rajput A Rodzilsky B, Rajput A. Accuracy of clinical diagnosis of Parkinsonism - a prospective study. Can J Neurol Sci 1991;18: 275-278.
38. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
39. 123I]βCIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
40. 11C] RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease. Neurology 1997;48:1578-1583.
41. 18F]dopa PET data. Arch Neurol 1994;51:237-243.
42. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1995;45:1995-2004.
43. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993;34:324-330.
44. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;47:1-9.
45. Wenning G, Tison F, Shlomo B, Daniel S, Quinn N. Multiple system atrophy: a review of 203 pathologically proven cases. Movement Disorders 1997;12:133-46.
46. 18F-DOPA uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
47. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993;328:176-183.
48. Effect of deprenyl on the progression of disability in early Parkinson's disease. Parkinson Study Group. N Engl J Med 1989;21:1364-1371.
49. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism. Ann Neurol 1994;36:759-64.
50. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
51. 123I-IPT and SPECT. Neurology 1997;48:A208.
52. 123I]b-CIT: assessment of progression in Parkinson's disease. Neurology 1997;48:A207.
53. Sawle G, Myers R. The role of positron emission tomography in the assessment of human transplantation. Trends Neurosci 1993; 16:260-264.
54. Tomac A, Lindqvist E, Lin L-F, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995; 373:335-339.
55. Olanow C, Kordower J, Freeman T. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996;19:102-109.
56. 123I]b-CIT SPECT. J Nucl Med 1995;36: 1175-1181.
57. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RJS. Striatal function in normal aging-implications for Parkinson's disease. Ann Neurol 1990;28:799-804.
58. Piccini P, Morrish P, Turjanski N, Sawle GV, Burn DJ, Weeks RA, et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-Dopa positron emission tomography study. Ann Neurol 1997;41:222-229.
59. 18F-DOPA and positron emission tomography. Neurology 1992;42:1894-1900.
60. Snow BJ, Peppard RF, Guttman M, Calne DB. Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. Arch Neurol 1990;47:870-874.
61. Golbe L. The genetics of Parkinson's disease: a reconsideration. Neurology 1990;40:7-16.
62. Polymeropoulos M, Higgins J, Golbe L, Johnson WG, Ide SE, Di Iorio G, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q12. Science 1996;1197-1199.